Expert thoracic oncologists discuss the importance of comprehensive molecular testing and optimal use of novel targeted agents in metastatic non-small cell lung cancer.
EP. 1: Lung Cancer: Molecular Testing
Alexander Spira, MD, PhD, FACP, shares an overview of the molecular testing needed for non–small cell lung cancer and his preferences for testing.
EP. 2: Mobocertinib for NSCLC With EGFR Exon 20 Insertion Mutations
Clinical trial data and implications for treating patients with metastatic non–small cell lung cancer with EGFR exon 20 insertion mutations with mobocertinib.
EP. 3: Adverse Events Associated With Mobocertinib
Common treatment-related adverse events associated with mobocertinib and other tyrosine kinase inhibitors, as well as management strategies are discussed.
EP. 4: New Therapies in Non–Small Cell Lung Cancer
Alexander Spira, MD, PhD, FACP, highlights emerging targeted agents to treat non–small cell lung cancer with actionable mutations.
EP. 5: Unmet Needs in Non–Small Cell Lung Cancer
Unmet needs including strategies to manage brain metastases in non–small cell lung cancer patients are presented.
EP. 6: Targeted Therapy for Metastatic Non–small Cell Lung Cancer
Mark A. Socinski, MD shares a brief overview of the biomarkers and FDA-approved targeted therapies for non–small cell lung cancers.
EP. 7: Non–small Cell Lung Cancer With EGFR Exon 20 Insertion
Rare drivers such as EGFR exon 20 insertions and what they mean for treatment of patients with metastatic non–small cell lung cancer.
EP. 8: EGFR Exon 20–Directed Therapy With Mobocertinib
Potential implications for treating patients with metastatic non–small cell lung cancers with EGFR exon 20 insertion mutations with mobocertinib, based on the EXCLAIM cohort.
EP. 9: EGFR Tyrosine Kinase Inhibitors and Brain Metastases
Commentary on the use of EGFR tyrosine kinase inhibitors and their efficacy on non–small cell lung cancer brain metastases.
EP. 10: Mobocertinib’s Safety Profile
Recommendations for mitigating and managing common treatment-related adverse events associated with mobocertinib and other tyrosine kinase inhibitors.
EP. 11: New Therapies for NSCLC With EGFR Exon 20 Insertions
Mark A. Socinski, MD, highlights the targeted agents available to treat non–small cell lung cancer with EGFR mutations.
EP. 12: EGFR Mutation Heterogeneity
Recommendations for EGFR testing in patients with non–small cell lung cancer based on the wide heterogeneity of these mutations.
Breast Cancer Index Risk Scores Are Prognostic for Premenopausal Women With HR+ Breast Cancer Receiving Adjuvant Endocrine Therapy
Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores
Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer
Everolimus Plus Adjuvant Endocrine Therapy Fails to Improve iDFS, OS in HR+/HER2- Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.